查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197330

靜脈治療和靜脈通路市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Intravenous (IV) Therapy and Vein Access Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計在預測期內（2022 年至 2027 年），靜脈療法 (IV) 和靜脈通路市場將以 5% 的複合年增長率增長。

COVID-19 大流行對靜脈治療 (IV) 和靜脈通路市場產生了重大影響。 例如，根據 2021 年 11 月發表的題為“針對 □□COVID-19 ARDS 的靜脈免疫球蛋白治療”的論文，靜脈注射免疫球蛋白 (IVIG) 被推薦用於中度至重度 COVID-19 相關急性呼吸窘迫綜合徵 (ARDS)，並且與血栓栓塞不良事件增加有關。 此類研究可能在短期內對市場增長產生負面影響。 然而，由於輸液療法的研究和開發增加以及對家庭藥物的需求增加，預計該市場在大流行後階段將出現積極增長。 例如，根據過敏和哮喘網絡 2022 年 3 月的更新，單克隆抗體通過靜脈內 (IV) 或單劑量注射給藥給診斷為 COVID-19 的人，並且這種療法對 COVID-19 有效。據信使用抗體可以幫助人體抵抗感染。 此外，根據2020年10月發表的論文《The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial》，其對COVID-19重症感染患者有效免疫球蛋白給藥有望改善臨床結果，並有助於顯著降低 SARS-CoV2 病毒感染的死亡率。 此類研究增加了對靜脈治療的需求，預計將在未來幾年推動靜脈治療 (IV) 和靜脈通路市場。

此外，慢性病的增加、全球手術數量的增加、靜脈藥物批准數量的增加以及靜脈治療和准入方面的技術進步不斷增加等因素也在推動市場增長。

全球範圍內慢性病發病率的上升和手術數量的增加推動了對靜脈治療和靜脈通路裝置的需求。 靜脈內治療用於輸送各種慢性疾病藥物，如類風濕性關節炎、克羅恩病、骨質疏鬆症、系統性狼瘡、多發性硬化症、牛皮癬和痛風。 根據 Atlas of MS 2020 年 9 月的一份報告，全球有 280 萬人患有多發性硬化症。 靜脈內治療也已成為外科手術的重要組成部分。 因此，增加外科手術將有助於市場增長。 例如，在一項名為“脊柱手術後靜脈注射利多卡因預防譫妄和減輕疼痛的臨床試驗 (LIMPP)”的正在進行的臨床試驗研究中，為了盡量減少患者群體中的譫妄和阿片類藥物的使用，研究了重建術後連續靜脈注射利多卡因脊柱手術。 該考試由加州大學主辦，預計將於 2024 年 9 月完成。 因此，此類研究將大大增加對靜脈注射治療的需求，並在未來幾年增加對靜脈注射和靜脈通路裝置的需求。

此外，根據 2021 年 6 月發表的一項題為“2020 年德國心臟手術報告”的研究報告。 根據德國胸心血管外科學會年度更新登記表，共有 92,809 例手術被歸類為經典意義上的心臟手術，其中 29,444 例為單冠狀動脈旁路移植術，35,469 例為單冠狀動脈旁路移植術。瓣膜手術和單心移植手術增加了 2%，達到 340 例。 鑑於靜脈治療在心臟直視手術出血管理中的關鍵作用，其需求預計將影響未來幾年 IV 和 IV 通路市場的增長。

此外，2021 年 9 月，B. Brown Medical 將推出帶有可選氣塞的新型 CARESAFE IV 給藥裝置。 CARESAFE IV Sets 是美國市場上第一個不含聚氯乙烯 (PVC) 和鄰苯二甲酸二乙基己酯 (DEHP) 的強大的 IV 給藥裝置組合。

然而，與靜脈治療相關的並發症和經驗豐富的醫療保健專業人員的短缺阻礙了市場的增長。

靜脈治療和准入市場趨勢

靜脈治療和准入市場，植入式端口將佔據主要市場份額

按類型來看，植入式端口細分市場預計將佔據較大份額。 植入式端口是皮下或靜脈內插入的裝置。 它通常插入胸部右上側鎖骨下方約 1 英寸處，用於抽血或給藥。

推動該細分市場增長的主要因素是技術進步和植入式端口的採用率不斷提高。 例如，2020 年 7 月，Angiodynamics 的 SmartPort+Implantable Port 獲得了美國食品藥品監督管理局 (FDA) 的 510(k) 許可和歐盟委員會的 CE 標誌。

此外，由於對植入式端口的認識提高，植入式端口的使用也在增加。 例如，2021 年 2 月，BD-India 在 2 月 4 日世界癌症日推出了一項名為“PortShala”的化學端口特殊教育計劃。 這些端口用於為癌症患者提供化學療法。 這項工作的重點是提高所有癌症利益相關者和護理人員之間有關化學端口植入、管理和維護的信息水平。

因此，由於上述因素，預計該行業在預測期內將出現顯著增長。

北美將佔據很大的市場份額，預計在預測期內也會如此

在北美，預計美國將佔據主要市場份額。 推動該國市場增長的主要因素是慢性病患病率增加和手術數量增加、醫療基礎設施改善和技術進步不斷增加。

例如，根據美國疾病控制和預防中心的數據，到 2020 年，美國將有大約 600,000 名婦女接受了子宮切除術。 根據全國婦女與家庭夥伴關係 2022 年 5 月的更新，美國的剖腹產率很高，現在大約有三分之一的新生兒是剖腹產。 所有這些程序都需要靜脈注射藥物和液體，從而推動了該國市場的增長。

一些市場參與者正在努力實施戰略計劃，從而為市場的增長做出貢獻。 例如，2022 年 3 月，多元化商業階段醫療技術公司 PAVmed Inc. 宣布，哥倫比亞巴蘭基亞 Clinica Porto Azul 的醫生將接受 IRB 批准的最多 40 名患者的首次試驗。在人體（FIH）臨床試驗中，公司將PortIO肌內註射系統植入三人體內，報告該裝置首次成功人體植入。 預計此類案例將大大有助於提高患者對 IV 治療和 IV 接入裝置的認識，從而增加該地區對 IV 治療和 IV 接入裝置的需求。

因此，由於上述因素，預計市場在預測期內將出現顯著增長。

靜脈療法和靜脈通路市場競爭對手分析

靜脈治療和通路市場是一個競爭激烈的市場，擁有全球和國際參與者。 主要參與者正在採用各種增長戰略，例如合作夥伴關係、協議、聯盟、新產品發布、地域擴張、兼併和收購，以增加他們的市場佔有率。 市場上的主要參與者包括 Becton、Dickinson and Company、Terumo Medical Corporation、Vygon SAS、Teleflex Incorporated、Fresenius Kabi 等。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 全球範圍內慢性病的增加和手術數量的增加
    • 輸液治療設備技術進步增加
  • 市場製約因素
    • 與輸液治療相關的並發症
    • 缺乏經驗豐富的醫療保健專業人員
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按類型
    • 輸液泵
    • 點滴套裝
    • 嵌入式端口
    • 中心靜脈導管
    • 其他產品
  • 通過申請
    • 擴容器
    • 藥物管理
    • 血液製品
    • 其他應用程序類型
  • 按銷售渠道
    • 醫院藥房
    • 零售藥房
    • 其他分銷渠道
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Polymedicure
    • Becton, Dickinson and Company
    • Tekni-Plex
    • Terumo Medical Corporation
    • Vygon SAS
    • Teleflex Incorporated
    • Fresenius Kabi
    • Smiths Medical, Inc.
    • Medtronic plc
    • Iradimed Corporation
    • ICU Medical, Inc
    • Baxter International
    • B. Braun Melsungen AG
    • AngioDynamics
    • Cardinal Health

第7章 市場機會與今後動向

簡介目錄
Product Code: 90580

The intravenous therapy (IV) and vein access market is expected to register a CAGR of 5% over the forecast period (2022-2027).

The COVID-19 pandemic has significantly impacted the intravenous therapy (IV) and vein access market. For instance, as per a November 2021 published article titled "Intravenous Immunoglobulin Therapy for COVID-19 ARDS", intravenous immunoglobulin (IVIG) did not significantly improve outcomes in moderate-to-severe COVID-19 associated acute respiratory distress syndrome (ARDS) and was associated with an increase in thromboembolic adverse events. Such studies are likely to have a short-term adverse impact on the market's growth. However, due to ongoing research and development activities in IV therapies and the rising demand for medication administration at home, the market is expected to grow positively in the post-pandemic phase. For instance, as per a March 2022 update by the Allergy & Asthma Network, monoclonal antibodies are given by intravenous (IV) or a single-dose injection to people diagnosed with COVID-19, and the therapy uses COVID-19 antibodies to help a person's body fight off the infection. In addition, as per an October 2020 published article titled "The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial," the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to improve the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Thus, such studies are anticipated to boost the demand for intravenous therapy, ultimately augmenting the intravenous therapy (IV) and vein access market over the coming years.

Furthermore, the market's growth can be attributed to factors such as the increasing incidences of chronic diseases, the growing number of surgeries worldwide, rising number of intravenous (IV) drug approvals, and increasing technological advancements in intravenous therapy (IV) and vein access.

The increasing number of incidences of chronic diseases and the growing number of surgeries worldwide is driving the demand for intravenous therapy and vein access devices. Intravenous therapy is used to deliver various medications for chronic conditions such as rheumatoid arthritis, Crohn's disease, osteoporosis, systemic lupus, multiple sclerosis, psoriasis, and gout. As per the September 2020 report by the Atlas of MS, 2.8 million people are living with Multiple Sclerosis around the globe. In addition, intravenous therapy is a key component of surgical procedures. Thus, the increasing number of surgical procedures contributes to market growth. For instance, an ongoing clinical trial study titled "A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain (LIMPP)" investigates continuous post-operative intravenous lidocaine infusion post-reconstructive spine surgery for minimizing delirium and opiate usage among the patient population. The University of California sponsored the trial, and it is expected to be completed by September 2024. Thus, such studies will greatly bolster the demand for IV therapy over the coming years, boosting the demand for IV and vein access devices.

Moreover, as per the research study published in June 2021, titled "German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery", a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. Since IV therapies play a vital role in managing blood loss caused due to open-heart surgeries, the demand for such treatments is likely to impact the growth of the IV and vein access market over the coming years.

Moreover, in September 2021, B. Braun Medical Inc. launched its new CARESAFE IV Administration Sets with Optional AirStop. CARESAFE IV Sets are the first robust portfolio of IV administration sets in the United States market that are not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP).

However, complications associated with intravenous therapy and a lack of experienced healthcare professionals hinder the market's growth.

Intravenous Therapy & Vein Access Market Trends

Implantable Ports Segment is Expected to Hold a Major Market Share in the Intravenous (IV) Therapy and Vein Access Market

By type, the implantable ports segment is expected to hold a major share in the market. Implantable ports are devices that are inserted under the skin and into a vein. They usually go in about an inch below the collarbone in the upper right chest for the withdrawal of blood or administration of drugs.

The major factors fuelling the segment's growth are the increasing number of technological advancements and the increasing adoption of implantable ports. For instance, in July 2020, AngioDynamics, Inc. received 510 (k) clearance from the United States Food & Drug Administration (FDA), as well as a CE Mark from the European Commission, for their SmartPort+ Implantable Port.

In addition, the use of implantable ports is increasing owing to the rising awareness of these devices among the patient population. For instance, in February 2021, BD-India launched a special educational program on chemo ports called PortShala on World Cancer Day, February 4th. These ports are used to deliver chemotherapy to cancer patients. The initiative focuses on upgrading information levels on implanting, administration, and maintenance of chemo ports among all cancer stakeholders and caregivers.

Thus, owing to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The United States is expected to hold a major share of the market in North America. The major factors fuelling the market growth in the country are the increasing prevalence of chronic diseases and the growing number of surgeries, improved healthcare infrastructure, and the rising number of technological advancements.

For instance, according to the Center for Disease Control and Prevention, in 2020, about 600,000 women in the United States had a hysterectomy. As per the National Partnership for Women & Families updates from May 2022, the C-section rate in the United States is high: about 1 in 3 women now gives birth by C-section. All these procedures require intravenous therapy for the administration of medications and fluids, which thus propels the market growth in the country.

Several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth. For instance, in March 2022, PAVmed Inc., a diversified commercial-stage medical technology company, reported that physicians at the Clinica Porto Azul in Barranquilla, Colombia, successfully implanted the company's PortIO Intraosseous Infusion System in three patients, the first human implants of the device, as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. Such instances will significantly contribute toward increasing patient awareness regarding IV therapies and systems, augmenting the demand for intravenous therapy (IV) and vein access devices within the region.

Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.

Intravenous Therapy & Vein Access Market Competitor Analysis

The intravenous (IV) therapy and vein access market is competitive with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Becton, Dickinson and Company, Terumo Medical Corporation, Vygon SAS, Teleflex Incorporated, and Fresenius Kabi, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Chronic Diseases and Growing Number of Surgeries Worldwide
    • 4.2.2 Increasing Technological Advancements in IV Therapy Devices
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Intravenous Therapy
    • 4.3.2 Lack of Experienced Healthcare Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Infusion Pumps
    • 5.1.2 Intravenous Sets
    • 5.1.3 Implantable Ports
    • 5.1.4 Central Venous Catheters
    • 5.1.5 Other Products
  • 5.2 By Application
    • 5.2.1 Volume Expander
    • 5.2.2 Medication Administration
    • 5.2.3 Blood-based Products
    • 5.2.4 Other Application Types
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Other Distribution Channel
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Polymedicure
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Tekni-Plex
    • 6.1.4 Terumo Medical Corporation
    • 6.1.5 Vygon SAS
    • 6.1.6 Teleflex Incorporated
    • 6.1.7 Fresenius Kabi
    • 6.1.8 Smiths Medical, Inc.
    • 6.1.9 Medtronic plc
    • 6.1.10 Iradimed Corporation
    • 6.1.11 ICU Medical, Inc
    • 6.1.12 Baxter International
    • 6.1.13 B. Braun Melsungen AG
    • 6.1.14 AngioDynamics
    • 6.1.15 Cardinal Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS